Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis.

Fernandez-Juarez G, Perez JV, Caravaca-Fontán F, Quintana L, Shabaka A, Rodriguez E, Gadola L, de Lorenzo A, Cobo MA, Oliet A, Sierra M, Cobelo C, Iglesias E, Blasco M, Galeano C, Cordon A, Oliva J, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN).

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1851-1858. doi: 10.2215/CJN.01390118. Epub 2018 Nov 5.

PMID:
30397027
2.

Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).

Goicoechea M, de Vinuesa SG, Quiroga B, Verde E, Bernis C, Morales E, Fernández-Juárez G, de Sequera P, Verdalles U, Delgado R, Torres A, Arroyo D, Abad S, Ortiz A, Luño J.

Cardiovasc Drugs Ther. 2018 Jun;32(3):255-263. doi: 10.1007/s10557-018-6802-1.

PMID:
29943364
3.

Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults.

Lepori N, Zand L, Sethi S, Fernandez-Juarez G, Fervenza FC.

Clin Kidney J. 2018 Apr;11(2):179-190. doi: 10.1093/ckj/sfx143. Epub 2018 Jan 9.

4.

Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients.

Goicoechea M, Sanchez-Niño MD, Ortiz A, García de Vinuesa S, Quiroga B, Bernis C, Morales E, Fernández-Juarez G, de Sequera P, Verdalles U, Verde E, Luño J.

Prostaglandins Leukot Essent Fatty Acids. 2017 Oct;125:8-13. doi: 10.1016/j.plefa.2017.08.009. Epub 2017 Aug 24.

PMID:
28987723
5.

Renal vasculitis presenting with acute kidney injury.

Villacorta J, Diaz-Crespo F, Acevedo M, Cavero T, Guerrero C, Praga M, Fernandez-Juarez G.

Rheumatol Int. 2017 Jun;37(6):1035-1041. doi: 10.1007/s00296-017-3697-2. Epub 2017 Mar 13.

PMID:
28289874
6.

What is the optimal level of vitamin D in non-dialysis chronic kidney disease population?

Molina P, Górriz JL, Molina MD, Beltrán S, Vizcaíno B, Escudero V, Kanter J, Ávila AI, Bover J, Fernández E, Nieto J, Cigarrán S, Gruss E, Fernández-Juárez G, Martínez-Castelao A, Navarro-González JF, Romero R, Pallardó LM.

World J Nephrol. 2016 Sep 6;5(5):471-81. doi: 10.5527/wjn.v5.i5.471.

7.

Circulating C3 levels predict renal and global outcome in patients with renal vasculitis.

Villacorta J, Diaz-Crespo F, Acevedo M, Cavero T, Guerrero C, Praga M, Fernandez-Juarez G.

Clin Rheumatol. 2016 Nov;35(11):2733-2740. Epub 2016 Aug 25.

PMID:
27562032
8.

Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis.

Fernandez-Juarez G, Villacorta J, Ruiz-Roso G, Panizo N, Martinez-Marín I, Marco H, Arrizabalaga P, Díaz M, Perez-Gómez V, Vaca M, Rodríguez E, Cobelo C, Fernandez L, Avila A, Praga M, Quereda C, Ortiz A.

Clin Kidney J. 2016 Jun;9(3):381-6. doi: 10.1093/ckj/sfw028. Epub 2016 May 24.

9.

Glomerular C3d as a novel prognostic marker for renal vasculitis.

Villacorta J, Diaz-Crespo F, Acevedo M, Guerrero C, Campos-Martin Y, García-Díaz E, Mollejo M, Fernandez-Juarez G.

Hum Pathol. 2016 Oct;56:31-9. doi: 10.1016/j.humpath.2016.05.015. Epub 2016 May 30.

PMID:
27257040
10.

Kidney injury after sodium phosphate solution beyond the acute renal failure.

Fernández-Juárez G, Parejo L, Villacorta J, Tato A, Cazar R, Guerrero C, Marin IM, Ocaña J, Mendez-Abreu A, López K, Gruss E, Gallego E.

Nefrologia. 2016 May-Jun;36(3):243-8. doi: 10.1016/j.nefro.2016.02.010. Epub 2016 Apr 15. English, Spanish.

11.

High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.

Fernández-Juárez G, Villacorta Perez J, Luño Fernández JL, Martinez-Martinez E, Cachofeiro V, Barrio Lucia V, Tato Ribera AM, Mendez Abreu A, Cordon A, Oliva Dominguez JA, Praga Terente M.

Nephrology (Carlton). 2017 May;22(5):354-360. doi: 10.1111/nep.12781.

PMID:
27003829
12.

The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study.

Diaz-Crespo F, Villacorta J, Acevedo M, Cavero T, Guerrero C, García Díaz E, Orradre JL, Martinez MA, Praga M, Fernandez-Juarez G.

Hum Pathol. 2016 Jun;52:119-27. doi: 10.1016/j.humpath.2016.01.015. Epub 2016 Feb 10.

PMID:
26980047
13.

A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.

Rojas-Rivera J, Fernández-Juárez G, Ortiz A, Hofstra J, Gesualdo L, Tesar V, Wetzels J, Segarra A, Egido J, Praga M.

Clin Kidney J. 2015 Oct;8(5):503-10. doi: 10.1093/ckj/sfv075. Epub 2015 Sep 24.

14.

Rapidly progressive IgA nephropathy: a form of vasculitis or a complement-mediated disease?

Rojas-Rivera J, Fernández-Juárez G, Praga M.

Clin Kidney J. 2015 Oct;8(5):477-81. doi: 10.1093/ckj/sfv095. Epub 2015 Sep 24.

15.

Antineutrophil cytoplasmic antibody negative pauci-immune extracapillary glomerulonephritis.

Villacorta J, Diaz-Crespo F, Acevedo M, Guerrero C, Mollejo M, Fernandez-Juarez G.

Nephrology (Carlton). 2016 Apr;21(4):301-7. doi: 10.1111/nep.12608.

PMID:
26369898
16.

Effectiveness of mycophenolate mofetil in C3 glomerulonephritis.

Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández-Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López-Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizábal S, de Córdoba SR, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN).

Kidney Int. 2015 Nov;88(5):1153-60. doi: 10.1038/ki.2015.227. Epub 2015 Jul 29.

PMID:
26221755
17.

Mycophenolate in refractory and relapsing lupus nephritis.

Rivera F, Mérida E, Illescas ML, López-Rubio E, Frutos MA, García-Frías P, Ramos C, Sierra M, Baltar J, Lucas J, Oliet A, Vigil A, Fernández-Juárez G, Segarra A, Praga M; Glomerular Spanish Glomerular Study Group (GLOSEN).

Am J Nephrol. 2014;40(2):105-12. doi: 10.1159/000365256. Epub 2014 Jul 30.

PMID:
25096639
18.

Combined angiotensin inhibition in diabetic nephropathy.

Quiroga B, Fernández Juárez G, Luño J.

N Engl J Med. 2014 Feb 20;370(8):777. doi: 10.1056/NEJMc1315504. No abstract available.

PMID:
24552329
19.

25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.

Fernández-Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J; PRONEDI Study Group.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1870-6. doi: 10.2215/CJN.00910113. Epub 2013 Oct 17.

20.

Mycophenolate as maintenance therapy for lupus nephritis with impaired renal function.

Rivera F, Illescas ML, López-Rubio E, Fulladosa J, Poveda R, Baltar J, Fernández-Juárez G, Ballarín J, Oliet A, Vigil A, Lucas J, Sierra M, Frutos MA, García-Frías P, Ramos C, Mérida E, Praga M, Segarra A.

Am J Nephrol. 2013;37(6):509-17. doi: 10.1159/000350756. Epub 2013 May 8.

PMID:
23689615

Supplemental Content

Loading ...
Support Center